Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melvin Spigelman

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
The Lancet. Respiratory Medicine|November 19, 2023
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trialBern-Thomas Nyang'wa, Catherine Berry, Emil Kazounis, et al.
The New England Journal of Medicine|December 22, 2022
A 24-Week, All-Oral Regimen for Rifampin-Resistant TuberculosisBern-Thomas Nyang'wa, Catherine Berry, Emil Kazounis, et al.
BMC Pulmonary Medicine|August 16, 2019
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV statusConor D Tweed, Angela M Crook, Rodney Dawson, et al.
The New England Journal of Medicine|March 5, 2020
Treatment of Highly Drug-Resistant Pulmonary TuberculosisFrancesca Conradie, Andreas H Diacon, Nosipho Ngubane, et al.
Antimicrobial Agents and Chemotherapy|March 24, 2022
Reply to Kaye and Belley, "Third-Generation Cephalosporin-Resistant <i>Enterobacterales</i> Are Critical Priority Pathogens, Too!"Mark S Butler, Valeria Gigante, Hatim Sati, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2024
Multi-year analysis of the global preclinical antibacterial pipeline: trends and gapsValeria Gigante, Richard A Alm, Daniela Melchiorri, et al.
Antimicrobial Agents and Chemotherapy|January 10, 2022
Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is NeededMark S Butler, Valeria Gigante, Hatim Sati, et al.
Lancet (London, England)|March 22, 2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosisRodney Dawson, Andreas H Diacon, Daniel Everitt, et al.
BMC Infectious Diseases|July 13, 2018
Toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor D Tweed, Angela M Crook, Evans I Amukoye, et al.
The Lancet. Respiratory Medicine|November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trialConor D Tweed, Rodney Dawson, Divan A Burger, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
The Lancet. Respiratory Medicine|November 19, 2023
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trialBern-Thomas Nyang'wa, Catherine Berry, Emil Kazounis, et al.
The New England Journal of Medicine|December 22, 2022
A 24-Week, All-Oral Regimen for Rifampin-Resistant TuberculosisBern-Thomas Nyang'wa, Catherine Berry, Emil Kazounis, et al.
BMC Pulmonary Medicine|August 16, 2019
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV statusConor D Tweed, Angela M Crook, Rodney Dawson, et al.
The New England Journal of Medicine|March 5, 2020
Treatment of Highly Drug-Resistant Pulmonary TuberculosisFrancesca Conradie, Andreas H Diacon, Nosipho Ngubane, et al.
Antimicrobial Agents and Chemotherapy|March 24, 2022
Reply to Kaye and Belley, "Third-Generation Cephalosporin-Resistant <i>Enterobacterales</i> Are Critical Priority Pathogens, Too!"Mark S Butler, Valeria Gigante, Hatim Sati, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2024
Multi-year analysis of the global preclinical antibacterial pipeline: trends and gapsValeria Gigante, Richard A Alm, Daniela Melchiorri, et al.
Antimicrobial Agents and Chemotherapy|January 10, 2022
Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is NeededMark S Butler, Valeria Gigante, Hatim Sati, et al.
Lancet (London, England)|March 22, 2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosisRodney Dawson, Andreas H Diacon, Daniel Everitt, et al.
BMC Infectious Diseases|July 13, 2018
Toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor D Tweed, Angela M Crook, Evans I Amukoye, et al.
The Lancet. Respiratory Medicine|November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trialConor D Tweed, Rodney Dawson, Divan A Burger, et al.
Pageof 3